Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
February 2014, Vol 5, No 1
February 2014, Vol 5, No 1
Abraxane Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer
By
Lisa A. Raedler, PhD, RPh
Drug Updates
February 2014, Vol 5, No 1
In September 2013, the US Food and Drug Administration (FDA) approved the cytotoxic agent nab-paclitaxel (paclitaxel protein-bound particles for injectable suspension, albumin-bound; Abraxane; Celgene Corporation) for first-line treatment of patients with metastatic adenocarcinoma of the pancreas in combination with gemcitabine.
Read Article
Task Force Recommends Annual Screening for Lung Cancer in High-Risk Populations
By
Neil Canavan
Lung Cancer
February 2014, Vol 5, No 1
The US Preventive Services Task Force (USPSTF) is recommending that individuals aged >55 years who have a history of heavy smoking be screened annually for lung cancer.
Read Article
Adjuvant Chemotherapy Benefit in Stage II Colon Cancers Is Small, May Even Cause Harm, Depending on Prognostic Markers
By
Wayne Kuznar
GI Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—The majority of patients with stage II colorectal cancer (CRC) have a good prognosis with surgery and gain little with adjuvant chemotherapy, said Richard M. Goldberg, MD, Physician-in-Chief, Ohio State University Comprehensive Cancer Center, Columbus, OH, at the 2014 Gastrointestinal Cancers Symposium.
Read Article
Dual-Vaccine Combination Improves Survival in Patients with Metastatic Pancreatic Cancer
By
Jayson Slotnik, JD, MPH
GI Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—A dual-vaccine strategy improved survival more than single vaccination of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Data from a randomized phase 2 trial were reported by Dung T. Le, MD, Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, at the 2014 Gastrointestinal Cancers Symposium.
Read Article
Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
By
Wayne Kuznar
Personalized Medicine
February 2014, Vol 5, No 1
New Orleans, LA—Those frustrated with low long-term remission rates in adult patients with acute lymphocytic leukemia (ALL) can find hope in the superior outcomes associated with treatment for pediatric ALL.
Read Article
Second-Generation Genomic Sequencing Offers Opportunities, Poses Challenges
By
Charles Bankhead
Personalized Medicine
February 2014, Vol 5, No 1
The quest for personalized medicine has come full circle with the US Food and Drug Administration (FDA)’s approval of the first high-throughput genomic sequencer, MiSeqDx, but challenges remain on several fronts before the technology’s full potential can be realized, according to the nation’s top health research administrator.
Read Article
I-SPY 2: First Results Based on Biomarkers/Genetic Signatures in Breast Cancer
Breast Cancer
,
Personalized Medicine
February 2014, Vol 5, No 1
San Antonio, TX—Veliparib plus carboplatin was identified as a worthy combination to move forward in trials of patients with triple-negative breast cancer (TNBC; ie, estrogen receptor–negative, progesterone receptor–negative, HER2-negative), a subtype of breast cancer with a very poor prognosis.
Read Article
PIK3CA Mutation Thwarts Neoadjuvant Anti-HER2 Therapy in Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Personalized Medicine
February 2014, Vol 5, No 1
>San Antonio, TX—Patients with HER2-positive breast cancer harboring a PIK3CA mutation had a significantly lower likelihood of achieving a pathologic complete response (pCR) to neoadjuvant anti-HER2 therapy, the results of 2 large clinical trials presented at the 2013 San Antonio Breast Cancer Symposium (SABCS) showed.
Read Article
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
By
Wayne Kuznar
2018 AONN+ Midyear Conference
,
Economics & Value
February 2014, Vol 5, No 1
New Orleans, LA—Peripheral T-cell lymphoma (PTCL) is associated with high resource utilization rates and high overall costs, according to a multicenter study presented at ASH 2013.
Read Article
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
>New Orleans, LA—New research has confirmed that 30-day readmission for reduced-toxicity conditioning allogeneic hematopoietic-cell transplantation (allo-HCT) is linked to greater 100-day posttransplant hospital charges.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma